Bright Minds Biosciences is a clinical-stage biotech developing selective serotonergic drugs for central-nervous-system disorders. Its chemistry platform targets highly selective 5-HT2A and 5-HT2C receptor agonists designed to avoid 5-HT2B activity linked to safety concerns. Pipeline work centers on conditions such as drug-resistant epilepsy, depression and other neurological and psychiatric indications.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -5.2 | — |
| Q3 2025 | 0 | — | -4.1 | — |
| Q4 2025 | 0 | — | -7.6 | — |
| Q1 2026 | 0 | — | -10.5 | — |
| Q2 2026 | 0 | — | -2.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Powerlaw Corp. (PWRL), Nexxen International Ltd. (NEXN), The York Water Company (YORW), REalloys Inc. (ALOY), Orange County Bancorp, Inc. (OBT), Ramaco Resources, Inc. (METC)